- Kuros Bioscience press release (OTCPK:CSBTF): Q1 Total Medical Device sales rose by 82% to USD 28.8 million (Q1 2024: USD 15.8 million) with monthly revenue surpassing USD 10.0 million for the first time
- Total Group EBITDA reached USD 2.0 million (Q1 2024: EBITDA of USD 1.2 million)
- Total Group adjusted EBITDA amounted to USD 3.3 million, equaling a margin of 11.6%.
